1645

Under the Paperwork Seduction Act of 1988	no persons are required to respond	U.S. Patent and Ti	PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE ormation unless it displays a valid OMB control number.
Under the Paperwork Seduction Act of 1939	Application Number		54,616
TRANSMITTAL	Filing Date	Janu	eary 22, 2002
FORM	First Named Invento	or Larry	S. BARAK
	Art Unit	164	5
(to be used for all correspondence after initial	Examiner Name	Unas	ssigned
Total Number of Pages in This Submission	4 Attorney Docket Nu	mber NRK	.10022
	ENCLOSURES (Ch	eck all that apply	)
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application  Reply to Missing Parts  under 37 CFR 1.52 or 1.53	required by ti 50-3218. Th	e on CD is hereby authorizing paper is submitt	
Firm Name	TURE OF APPLICANT,	ATTORNET, C	DR AGENT
Hutchison & Mason PLL	C		
Signature / Sung 1.	Slliott		
Printed name Joshua T. Elliott			
Date March 2, 20	005	Reg. No.	43,603
	ERTIFICATE OF TRANS		ILING sited with the United States Postal Service with

PE JCTO

the date shown below:

Typed or printed name

Jennie R. Spead

Date 3/02/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO

sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Larry S. BARAK et al.

Application No.: 10/054,616 Group Art Unit: 1645

Filing Date: January 22, 2002 Examiner: Unassigned

Title: Constitutively Desensitized G Confirmation No.: 7096

**Protein-Coupled Receptors** 

## FOURTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. A copy of each of the documents cited and required by 37 C.F.R. § 1.98 is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO/SB/08. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The listed documents were cited in a European Search Report in a corresponding European application. A copy of the Search Report is enclosed.

The cited documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

Attorney Docket No. NRK.10022 Page 2 of 2

Application No.: 10/054,616

The Director is hereby authorized to charge any appropriate fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-3218.

Respectfully submitted,

**HUTCHISON & MASON PLLC** 

Date: March 2, 2005

Joshua T. Elliott

Registration No. 43,603

P.O. Box 31686 Raleigh, NC 27612 +1.919.829.9600

PTO/SB/08A/08-03)
Approved for use through 07/31/2006. OAR 0651-0031
US Patent & Tradement Office: U.S. DEPATRMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO INFORMATION DISCLOSURE 10/054,616 **Application Number** STATEMENT BY APPLICANT January 22, 2002 **Filing Date** BARAK, Larry S. **First Named Inventor** MAR 0 4 2005 **Group Art Unit** 1645 Unknown **Examiner Name** PRADEMA Attorney Docket No: NRK.10022 Sheet 1 of 1

	US PATENT DOCUMENTS					
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Foreign Document No	Publication Date	Pages,Columns,Lines,Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report	

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report		
	BIRNBAUMER, MARIEL, et al., "Molecular Cloning of the Receptor for Human Antidiuretic Hormone", Nature, vol. 357, no. 6376, pp. 333-335 (1992).			
	ROSENTHAL, WALTER, et al., "Nephrogenic Diabetes Insipidus: A V2 Vasopressin Receptor Unable to Stimulate Adenylyl Cyclase", Journal of Biological Chemistry, vol. 268, no. 18, pp. 13030-13033 (1993).			
	SIEGL, PETER K. S., et al., "In Vivo Pharmacology of L-158,809, a New Highly Potent and Selective Nonpeptide Angiotensin II Receptor Antagonist", Journal of Pharmacology and Experimental Therapeutics, vol. 262, no. 1, pp. 139-144 (1 July 1992).			

**EXAMINER** 

**DATE CONSIDERED**